It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

Otulfi ® is an ustekinumab biosimilar for the reference product Stelara ® (ustekinumab ... in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical ...

Biosimilars like SELARSDI provide cost-saving ... initiating use of SELARSDI in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice ...

PYZCHIVA becomes Samsung Bioepis’ fifth biosimilar and third immunology ... of PYZCHIVA in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek ...

“Biosimilars like SELARSDI create opportunities ... initiating use of SELARSDI in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice ...